Document:

EXHIBIT
10.1

 

REGISTRATION
RIGHTS AGREEMENT 

 

THIS
REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of April 17, 2022, to be effective as of the
Closing (as defined in the Merger Agreement (as defined below)), by and among Flexible Solutions International Inc., an Alberta, Canada
corporation (including any of its successors or assigns, the “Company”), and the other parties hereto identified as
an “Investor” on the signature pages and Schedule A hereto (together with any person or entity who hereafter becomes
a party to this Agreement pursuant to Section 6.2 of this Agreement, an “Investor” and collectively the “Investors”).

 

WHEREAS,
the Company, Lygos, Inc., (“Lygos”) a Delaware corporation, FSI Merger Sub I, Inc., a Delaware corporation (“Merger
Sub I”), and FSI Merger Sub II, Inc., a Delaware corporation (“Merger Sub II”), have entered into that certain
Agreement and Plan of Merger and Reorganization dated as of [ ], 2022 (the “Merger Agreement”), pursuant to which
(i) Merger Sub I will merge with and into Lygos, and Lygos shall continue as the surviving entity and wholly owned subsidiary of the
Company (the “First Merger”) and (ii) immediately thereafter as part of the same overall transaction, Lygos will merge
with and into Merger Sub II, and Merger Sub II will continue as the surviving entity and wholly owned subsidiary of the Company (the
“Second Merger” and, collectively or in seriatim with the First Merger, the “Merger”);

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.
DEFINITIONS. The following capitalized terms used herein have the following meanings:

 

“Actions”
means actions, suits, litigations, arbitrations, mediations, claims, charges, complaints, inquiries, proceedings, hearings, audits, investigations
or reviews by or before any Governmental Entity.

 

“Adverse
Disclosure” shall mean any public disclosure of material non-public information, which disclosure, in the good faith judgment
of the Board, after consultation with counsel to the Company, (i) would be required to be made in any Registration Statement or prospectus
in order for the applicable Registration Statement or prospectus not to contain any untrue statement of a material fact or omit to state
a material fact necessary to make the statements contained therein (in the case of any prospectus and any preliminary prospectus, in
the light of the circumstances under which they were made) not misleading, (ii) would not be required to be made at such time if the
Registration Statement were not being filed, and (iii) the Company has a bona fide business purpose for not making such information public.

 

“Agreement”
is defined in the preamble to this Agreement.

 

“Block
Trade” means any non-marketed underwritten offering taking the form of a block trade to a financial institution, QIB or Institutional
Accredited Investor, bought deal, over-night deal or similar transaction effected pursuant to a Registration Statement without substantial
marketing efforts prior to pricing.

 

“Board”
means the Board of Directors of the Company.

 

“Business
Day” means a day other than a Saturday, Sunday or other day on which commercial banks in New York, New York are authorized
or required by law to close.

 

“Closing
Date” is defined in the Merger Agreement.

 

“Commission”
means the Securities and Exchange Commission, or any other Federal agency then administering the Securities Act or the Exchange Act.

 

“Company”
is defined in the preamble to this Agreement.

 

“Effectiveness
Period” is defined in Section 3.1.2.

 

    	1

    	 

    

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated thereunder,
all as the same shall be in effect at the time.

 

“Form
S-1” means a Registration Statement on Form S-1.

 

“Form
S-3” means a Registration Statement on Form S-3 or any similar short-form registration that may be available at such time.

 

“Founder
Shares” means all shares of capital stock of the Company held or hereafter acquired by Daniel O’Brien.

 

“Governmental
Entity” means any federal, state or local government, any political subdivision thereof or any court, administrative or regulatory
agency, department, court, instrumentality, tribunal, arbitrator, legislative body, authority, body, program, plan, office, board, rate
setting agency, bureau, division, official or instrumentality, or commission or other governmental authority or agency, or arbitral body
(public or private), in the United States or in a foreign jurisdiction and including any contractors of a Governmental Entity, department
or agency as authorized by law, and acting pursuant to the terms and conditions of any such contract.

 

“Indemnified
Party” is defined in Section 4.3.

 

“Indemnifying
Party” is defined in Section 4.3.

 

“Institutional
Accredited Investor” means an institutional “accredited” investor as defined in Rule 501(a) of Regulation D under
the Securities Act.

 

“Investor”
is defined in the preamble to this Agreement.

 

“Investor
Indemnified Party” is defined in Section 4.1.

 

“Joinder”
is defined in Section 6.2.

 

“Legal
Dispute” means any Action among the parties, whether arising in contract, tort or otherwise, arising in connection with any
disagreement, dispute, controversy or claim arising out of or relating to this Agreement or any related document or any of the transaction
contemplated hereby or thereby.

 

“Maximum
Number of Shares” is defined in Section 2.2.2.

 

“Merger”
is defined in the preamble to this Agreement.

 

“Merger
Agreement” is defined in the preamble to this Agreement.

 

“Merger
Shares” is defined in the preamble to this Agreement.

 

“Merger
Sub I” is defined in the preamble to this Agreement.

 

“Merger
Sub II” is defined in the preamble to this Agreement.

 

“Misstatement”
shall mean an untrue statement of a material fact or an omission to state a material fact required to be stated in a Registration Statement
or prospectus, or necessary to make the statements in a Registration Statement or prospectus (in the case of a prospectus, in the light
of the circumstances under which they were made) not misleading.

 

    	2

    	 

    

 

“Permitted
Transferee” means (i) the members of an Investor’s immediate family (for purposes of this Agreement, “immediate
family” shall mean with respect to any natural person, any of the following: such person’s spouse, the siblings of such
person and his or her spouse, and the direct descendants and ascendants (including adopted and step children and parents) of such person
and his or her spouses and siblings); (ii) any trust for the direct or indirect benefit of an Investor or the immediate family of an
Investor; (iii) if an Investor is a trust, to the trustor or beneficiary of such trust or to the estate of a beneficiary of such trust;
(iv) any officer, director, general partner, limited partner, shareholder, member, or owner of similar equity interests in an Investor;
(v) any affiliate of an Investor or the immediate family of such affiliate or (vi) any affiliate of an immediate family of the Investor.

 

“Piggy-Back
Registration” is defined in Section 2.4.1.

 

“Pro
Rata” is defined in Section 2.2.2.

 

“QIB”
means “qualified institutional buyer” as defined in Rule 144A under the Securities Act.

 

“Registration”
mean a registration effected by preparing and filing a registration statement or similar document in compliance with the requirements
of the Securities Act, and the applicable rules and regulations promulgated thereunder, and such registration statement becoming effective.

 

“Registrable
Securities” means the Founder Shares; provided that any Founder Shares which are hereafter acquired shall only be deemed
to be “Registrable Securities” if at the time of the acquisition of such shares, the recipient of such Founder Shares executes
a Joinder acknowledging the terms and conditions of this Agreement. As to any particular Registrable Securities, such securities shall
cease to be Registrable Securities when: (a) a Registration Statement with respect to the sale of such securities shall have become effective
under the Securities Act and such securities shall have been sold, transferred, disposed of or exchanged in accordance with such Registration
Statement; (b) such securities shall have been otherwise transferred, new certificates or book entry provisions for them not bearing
a legend restricting further transfer shall have been delivered by the Company and subsequent public distribution of them shall not require
registration under the Securities Act; (c) such securities shall have ceased to be outstanding; (d) such securities may be sold without
registration pursuant to Rule 144 or any successor rule promulgated under the Securities Act (but with no limitation as to volume); and
(e) such securities have been sold to, or through, a broker, dealer or underwriter in a public distribution or other public securities
transaction.

 

“Registration
Statement” means a registration statement filed by the Company or its successor with the Commission in compliance with the
Securities Act and the rules and regulations promulgated thereunder for a public offering and sale of equity securities, or securities
or other obligations exercisable or exchangeable for, or convertible into, equity securities (other than a registration statement on
Form S-4 or Form S-8, or their successors, or any registration statement covering only securities proposed to be issued in exchange for
securities or assets of another entity).

 

“Resale
Shelf Registration Statement” is defined in Section 2.1.1.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder,
all as the same shall be in effect at the time.

 

“Underwriter”
means a securities dealer who purchases any Registrable Securities as principal in an underwritten offering and not as part of such dealer’s
market-making activities.

 

    	3

    	 

    

 

2.
REGISTRATION RIGHTS.

 

2.1
Resale Shelf Registration Rights.

 

2.1.1
Registration Statement Covering Resale of Registrable Securities. Subject to compliance by the Investors with Section 3.4,
the Company shall prepare and file or cause to be prepared and filed with the Commission, no later than sixty (60) calendar days following
the Closing Date, a Registration Statement on Form S-3 or its successor form, or, if the Company is ineligible to use Form S-3, a Registration
Statement on Form S-1, for an offering to be made on a continuous basis pursuant to Rule 415 of the Securities Act registering the resale
from time to time pursuant to any method or combination of methods legally available to, and requested by, the Investors of all of the
Registrable Securities then held by such Investors that are not covered by an effective resale registration statement (the “Resale
Shelf Registration Statement”). The Company shall use commercially reasonable efforts to cause the Resale Shelf Registration
Statement to be declared effective as soon as practicable after filing, but in any event no later than the earlier of (i) ninety (90)
calendar days (or one hundred twenty (120) calendar days if the Commission notifies the Company that it will “review” the
Registration Statement) after the date of this Agreement and (ii) the tenth (10th) Business Day after the date the Company is notified
(orally or in writing, whichever is earlier) by the Commission that such Registration Statement will not be “reviewed” or
will not be subject to further review, and, once effective, to keep the Resale Shelf Registration Statement continuously effective under
the Securities Act at all times until the expiration of the Effectiveness Period. In the event that the Company files a Form S-1 pursuant
to this Section 2.1, the Company shall use commercially reasonable efforts to convert the Form S-1 to a Form S-3 as soon as practicable
after the Company is eligible to use Form S-3. When effective, a Registration Statement filed pursuant to this Section 2.1 (including
any documents incorporated therein by reference) will comply as to form in all material respects with all applicable requirements of
the Securities Act and the Exchange Act.

 

2.1.2
Notification and Distribution of Materials. The Company shall notify the Investors in writing of the effectiveness of the Resale
Shelf Registration Statement and shall furnish to them, without charge, such number of copies of the Resale Shelf Registration Statement
(including any amendments, supplements and exhibits), the prospectus contained therein (including each preliminary prospectus and all
related amendments and supplements) and any documents incorporated by reference in the Resale Shelf Registration Statement or such other
documents as the Investors may reasonably request in order to facilitate the sale of the Registrable Securities in the manner described
in the Resale Shelf Registration Statement.

 

2.1.3
Amendments and Supplements. Subject to the provisions of Section 2.1.1, the Company shall promptly prepare and file with
the Commission from time to time such amendments and supplements to the Resale Shelf Registration Statement and prospectus used in connection
therewith as may be necessary to keep the Resale Shelf Registration Statement effective and to comply with the provisions of the Securities
Act with respect to the disposition of all the Registrable Securities during the Effectiveness Period.

 

2.1.4
Notice of Certain Events. The Company shall promptly notify the Investors in writing of any request by the Commission for any
amendment or supplement to, or additional information in connection with, the Resale Shelf Registration Statement required to be prepared
and filed hereunder (or prospectus relating thereto). The Company shall promptly notify each Investor in writing of the filing of the
Resale Shelf Registration Statement or any prospectus, amendment or supplement related thereto or any post-effective amendment to the
Resale Shelf Registration Statement and the effectiveness of any post-effective amendment.

 

2.1.5
Block Trade. If the Company shall receive a request from the holders of Registrable Securities with an estimated market value
of at least $10,000,000 that such holders wish to effect the sale of all or any portion of the Registrable Securities in a Block Trade,
then the Company shall, as expeditiously as possible, use commercially reasonable efforts to facilitate the offering of such Registrable
Securities for which such requesting holder has requested in such Block Trade, and in any event, within 72 hours of receipt of such request.

 

    	4

    	 

    

 

2.2
Piggy-Back Registration.

 

2.2.1
Piggy-Back Rights. If at any time, subject to compliance by the Investors with Section 3.4, the Company proposes to file
a Registration Statement under the Securities Act with respect to an offering of equity securities, or securities or other obligations
exercisable or exchangeable for, or convertible into, equity securities, by the Company for its own account or for equityholders of the
Company for their account, other than a Registration Statement (i) filed in connection with any employee share option or other benefit
plan, (ii) for an exchange offer or offering of securities solely to the Company’s existing shareholders, (iii) for an offering
of debt that is convertible into equity securities of the Company, (iv) for a dividend reinvestment plan, or (v) for a corporate reorganization
or transaction under Rule 145 of the Securities Act, then the Company shall (x) give written notice of such proposed filing to the holders
of Registrable Securities as soon as practicable but in no event less than five (5) calendar days before the anticipated filing date,
which notice shall describe the amount and type of securities to be included in such offering, the intended method(s) of distribution,
and the name of the proposed managing Underwriter or Underwriters, if any, of the offering, and (y) offer to the holders of Registrable
Securities in such notice the opportunity to register the sale of such number of shares of Registrable Securities as such holders may
request in writing within three (3) calendar days following receipt of such notice (a “Piggy-Back Registration”).
The Company shall cause such Registrable Securities to be included in such registration and shall use its best efforts to cause the managing
Underwriter or Underwriters of a proposed underwritten offering to permit the Registrable Securities requested to be included in a Piggy-Back
Registration on the same terms and conditions as any similar securities of the Company and to permit the sale or other disposition of
such Registrable Securities in accordance with the intended method(s) of distribution thereof. All holders of Registrable Securities
proposing to distribute their securities through a Piggy-Back Registration that involves an Underwriter or Underwriters shall enter into
an underwriting agreement in customary form with the Underwriter or Underwriters selected for such Piggy-Back Registration.

 

2.2.2
Reduction of Piggy-Back Offering. If the managing Underwriter or Underwriters for a Piggy-Back Registration that is to be an underwritten
offering advises the Company and the holders of Registrable Securities that have requested to participate in such Piggy-Back Registration
in writing that the dollar amount or number of securities of the Company which the Company desires to sell for its own account, taken
together with securities of the Company, if any, as to which registration has been demanded pursuant to written contractual arrangements
with persons other than the holders of Registrable Securities hereunder and the Registrable Securities as to which registration has been
requested under this Section 2.2, exceeds the maximum dollar amount or maximum number of securities that can be sold in such offering
without adversely affecting the proposed offering price, the timing, the distribution method, or the probability of success of such offering
(such maximum dollar amount or maximum number of shares, as applicable, the “Maximum Number of Shares”), then the
Company shall include in any such registration:

 

(i)
If the registration is undertaken for the Company’s account: (A) first, the securities of the Company that the Company desires
to sell that can be sold without exceeding the Maximum Number of Shares; (B) second, to the extent that the Maximum Number of Shares
has not been reached under the foregoing clause (A), the Registrable Securities, as to which registration has been requested pursuant
to the terms of this Agreement that can be sold without exceeding the Maximum Number of Shares, pro rata in accordance with the number
of shares that each such person has requested be included in such registration, regardless of the number of shares held by each such
person (such proportion is referred to herein as “Pro Rata”; and (C) third, to the extent that the Maximum Number
of Shares has not been reached under the foregoing clauses (A) and (B), the securities of the Company for the account of other persons
that the Company is obligated to register pursuant to written contractual piggy-back registration rights with such persons, other than
pursuant to this Agreement, and that can be sold without exceeding the Maximum Number of Shares;

 

(ii)
If the registration is undertaken as a demand pursuant to contractual rights with the Company, other than this Agreement, (A) first,
the securities of the Company for the account of the persons entitled to such contractual rights making such demand that can be sold
without exceeding the Maximum Number of Shares; (B) second, to the extent that the Maximum Number of Shares has not been reached under
the foregoing clause (A), the Registrable Securities, as to which registration has been requested pursuant to the terms of this Agreement,
that can be sold without exceeding the Maximum Number of Shares, Pro Rata; (C) third, to the extent that the Maximum Number of Shares
has not been reached under the foregoing clauses (A) and (B), the securities of the Company that the Company desires to sell that can
be sold without exceeding the Maximum Number of Shares; and (D) fourth, to the extent that the Maximum Number of Shares has not been
reached under the foregoing clauses (A), (B) and (C), the securities of the Company for the account of any other persons that the Company
is obligated to register pursuant to written contractual arrangements with such persons, other than this Agreement, that can be sold
without exceeding the Maximum Number of Shares.

 

    	5

    	 

    

 

2.2.3
Withdrawal. Any holder of Registrable Securities may elect to withdraw such holder’s request for inclusion of Registrable
Securities in any Piggy-Back Registration by giving written notice to the Company of such request to withdraw prior to the effectiveness
of the Registration Statement. The Company (whether on its own determination or as the result of a withdrawal by persons making a demand
pursuant to written contractual obligations) may withdraw a Registration Statement at any time prior to the effectiveness of such Registration
Statement. Notwithstanding any such withdrawal, the Company shall pay all expenses incurred by the holders of Registrable Securities
in connection with such Piggy-Back Registration as provided in Section 3.3. If the Registration Statement has been withdrawn,
or if any Registrable Securities have been withdrawn without the consent of the Investor, the Company will promptly file a new Registration
Statement to register the Registrable Securities.

 

3.
REGISTRATION PROCEDURES.

 

3.1
Filings; Information. Whenever the Company is required to effect the registration of any Registrable Securities pursuant to Section
2, the Company shall use commercially reasonable efforts to effect the registration and sale of such Registrable Securities in accordance
with the intended method(s) of distribution thereof as expeditiously as practicable, and in connection with any such request:

 

3.1.1
Copies. The Company shall, prior to filing a Registration Statement or prospectus, or any amendment or supplement thereto, furnish
without charge to the holders of Registrable Securities included in such registration, and such holders’ legal counsel, copies
of such Registration Statement as proposed to be filed, each amendment and supplement to such Registration Statement (in each case, including
all exhibits thereto and documents incorporated by reference therein), the prospectus included in such Registration Statement (including
each preliminary prospectus), and such other documents as the holders of Registrable Securities included in such registration or legal
counsel for any such holders may request in order to facilitate the disposition of the Registrable Securities owned by such holders.

 

3.1.2
Amendments and Supplements. The Company shall prepare and file with the Commission such amendments, including post-effective amendments,
and supplements to such Registration Statement and the prospectus used in connection therewith as may be necessary to keep such Registration
Statement effective and in compliance with the provisions of the Securities Act until all Registrable Securities and other securities
covered by such Registration Statement have been disposed of in accordance with the intended method(s) of distribution set forth in such
Registration Statement (the “Effectiveness Period”).

 

3.1.3
Notification. After the filing of a Registration Statement, the Company shall promptly, and in no event more than three (3) Business
Days after such filing, notify the holders of Registrable Securities included in such Registration Statement of such filing, and shall
further notify such holders promptly and confirm such advice in writing in all events within three (3) Business Days of the occurrence
of any of the following: (i) when such Registration Statement becomes effective; (ii) when any post-effective amendment to such Registration
Statement becomes effective; (iii) the issuance or threatened issuance by the Commission of any stop order (and the Company shall take
all actions required to prevent the entry of such stop order or to remove it if entered); and (iv) any request by the Commission for
any amendment or supplement to such Registration Statement or any prospectus relating thereto or for additional information or of the
occurrence of an event requiring the preparation of a supplement or amendment to such prospectus so that, as thereafter delivered to
the purchasers of the securities covered by such Registration Statement, such prospectus will not contain an untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, and
promptly make available to the holders of Registrable Securities included in such Registration Statement any such supplement or amendment;
except that before filing with the Commission a Registration Statement or prospectus or any amendment or supplement thereto, excluding
documents incorporated by reference, the Company shall furnish to the holders of Registrable Securities included in such Registration
Statement and to the legal counsel for any such holders, copies of all such documents proposed to be filed sufficiently in advance of
filing to provide such holders and legal counsel with a reasonable opportunity to review such documents and comment thereon.

 

    	6

    	 

    

 

3.1.4
Securities Laws Compliance. The Company shall use commercially reasonable efforts to (i) register or qualify the Registrable Securities
covered by the Registration Statement under such securities or “blue sky” laws of such jurisdictions in the United States
as the holders of Registrable Securities included in such Registration Statement (in light of their intended plan of distribution) may
reasonably request and (ii) take such action necessary to cause such Registrable Securities covered by the Registration Statement to
be registered with or approved by such other governmental authorities as may be necessary by virtue of the business and operations of
the Company and do any and all other acts and things that may be necessary or advisable to enable the holders of Registrable Securities
included in such Registration Statement to consummate the disposition of such Registrable Securities in such jurisdictions; provided,
however, that the Company shall not be required to qualify generally to do business in any jurisdiction where it would not otherwise
be required to qualify but for this paragraph or subject itself to taxation in any such jurisdiction.

 

3.1.5
Agreements for Disposition. The Company shall enter into customary agreements (including, if applicable, an underwriting agreement
in customary form) and take such other actions as are reasonably required in order to expedite or facilitate the disposition of such
Registrable Securities.

 

3.1.6
Cooperation. The principal executive officer of the Company, the principal financial officer of the Company, the principal accounting
officer of the Company (if different from the principal financial officer) and all other officers and members of the management of the
Company shall reasonably cooperate fully in any offering of Registrable Securities hereunder, which cooperation shall include, without
limitation, the preparation of the Registration Statement with respect to such offering and all other offering materials and related
documents, and participation in meetings with Underwriters, attorneys, accountants and potential investors.

 

3.1.7
Transfer Agent. The Company shall provide and maintain a transfer agent and registrar for the Registrable Securities.

 

3.1.8
Records. Upon execution of confidentiality agreements, the Company shall make available for inspection by the holders of Registrable
Securities included in such Registration Statement, any Underwriter participating in any disposition pursuant to such registration statement
and any attorney, accountant or other professional retained by any holder of Registrable Securities included in such Registration Statement
or any Underwriter, all financial and other records, pertinent corporate documents and properties of the Company, as shall be reasonably
necessary to enable them to exercise their due diligence responsibility, and cause the Company’s officers, directors and employees
to supply all information requested by any of them in connection with such Registration Statement.

 

3.1.9
Earnings Statement. The Company shall comply with all applicable rules and regulations of the Commission and the Securities Act,
and make available to its shareholders, as soon as practicable, an earnings statement covering a period of twelve (12) months, which
earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder.

 

3.1.10
Listing. The Company shall use commercially reasonable efforts to cause all Registrable Securities included in any Registration
Statement to be listed on such exchanges or otherwise designated for trading in the same manner as similar securities issued by the Company
are then listed or designated.

 

    	7

    	 

    

 

3.2
Obligation to Suspend Distribution. Upon receipt of written notice from the Company that a Registration Statement or prospectus
contains a Misstatement, each of the Investors shall forthwith discontinue disposition of Registrable Securities until he, she or it
has received copies of a supplemented or amended prospectus correcting the Misstatement (it being understood that the Company hereby
covenants to prepare and file such supplement or amendment as soon as practicable after the time of such notice), or until he, she or
it is advised in writing by the Company that the use of the prospectus may be resumed. If the filing, initial effectiveness or continued
use of a Registration Statement in respect of any Registration at any time would require the Company to make an Adverse Disclosure or
would require the inclusion in such Registration Statement of financial statements that are unavailable to the Company for reasons beyond
the Company’s control, the Company may, upon giving prompt written notice of such action to the Investors, delay the filing or
initial effectiveness of, or suspend use of, such Registration Statement for the shortest period of time, but in no event more than one
hundred and twenty (120) calendar days in any consecutive 12-month period, determined in good faith by the Company to be necessary for
such purpose. In the event the Company exercises its rights under the preceding sentence, the Investors agree to suspend, immediately
upon their receipt of the notice referred to above, their use of the prospectus relating to any Registration in connection with any sale
or offer to sell Registrable Securities. The Company shall immediately notify the Investors of the expiration of any period during which
it exercised its rights under this Section 3.2.

 

3.3
Registration Expenses. Subject to Section 2.1.7, the Company shall bear all costs and expenses incurred in connection with
the Resale Shelf Registration Statement pursuant to Section 2.1, any Piggy-Back Registration pursuant to Section 2.2.1,
and all expenses incurred in performing or complying with its other obligations under this Agreement, whether or not the Registration
Statement becomes effective, including, without limitation: (i) all registration and filing fees; (ii) fees and expenses of compliance
with securities or “blue sky” laws (including fees and disbursements of counsel in connection with blue sky qualifications
of the Registrable Securities); (iii) printing expenses; (iv) the Company’s internal expenses (including, without limitation, all
salaries and expenses of its officers and employees); (v) the fees and expenses incurred in connection with the listing of the Registrable
Securities as required by Section 3.1.10; (vii) Financial Industry Regulatory Authority, Inc. fees; (vii) fees and disbursements
of counsel for the Company and fees and expenses for independent certified public accountants retained by the Company; (viii) the reasonable
fees and expenses of any special experts retained by the Company in connection with such registration; and (ix) the reasonable fees and
expenses of one legal counsel selected by the holders of a majority-in-interest of the Registrable Securities included in such registration
not to exceed $75,000. The Company shall have no obligation to pay any underwriting discounts or selling commissions attributable to
the Registrable Securities being sold by the holders thereof, which underwriting discounts or selling commissions shall be borne by such
holders, but the Company shall pay any underwriting discounts or selling commissions attributable to the securities it sells for its
own account. Additionally, in an underwritten offering, all selling shareholders and the Company shall bear the expenses of the Underwriter
pro rata in proportion to the respective amount of shares each is selling in such offering.

 

3.4
Information. The holders of Registrable Securities shall promptly provide such information and affidavits as may reasonably be
requested by the Company, or the managing Underwriter, if any, in connection with the preparation of any Registration Statement, including
amendments and supplements thereto, in order to effect the registration of any Registrable Securities under the Securities Act and in
connection with the Company’s obligation to comply with Federal and applicable state securities laws.

 

3.5
Other Obligations. At any time and from time to time in connection with a sale or transfer of Registrable Securities exempt from
registration under the Securities Act or through any broker-dealer transactions described in the plan of distribution set forth within
any prospectus and pursuant to the Registration Statement of which such prospectus forms a part, the Company shall, subject to the receipt
of customary documentation required from the applicable holders in connection therewith and compliance with applicable laws, (i) promptly
instruct its transfer agent to remove any restrictive legends applicable to the Registrable Securities being sold or transferred and
(ii) cause its legal counsel to deliver the necessary legal opinions, if any, to the transfer agent in connection with the instruction
under subclause clause (i). In addition, the Company shall cooperate reasonably with, and take such customary actions as may reasonably
be requested by such holders in connection with the aforementioned sales or transfers.

 

    	8

    	 

    

 

4.
INDEMNIFICATION AND CONTRIBUTION.

 

4.1
Indemnification by the Company. The Company agrees to indemnify and hold harmless each Investor and each other holder of Registrable
Securities, and each of their respective affiliates and each of their respective officers, employees, directors, partners, members, attorneys
and agents, and each person, if any, who controls an Investor and each other holder of Registrable Securities (within the meaning of
Section 15 of the Securities Act or Section 20 of the Exchange Act) (each, an “Investor Indemnified Party”), from
and against any expenses, losses, judgments, claims, damages or liabilities, whether joint or several, arising out of or based upon any
untrue statement (or allegedly untrue statement) of a material fact contained in any Registration Statement filed pursuant to this Agreement
under which the sale of such Registrable Securities was registered under the Securities Act, any preliminary prospectus, final prospectus
or summary prospectus contained in the Registration Statement, or any amendment or supplement to such Registration Statement, or arising
out of or based upon any omission (or alleged omission) to state a material fact required to be stated therein or necessary to make the
statements therein not misleading, or any violation by the Company of the Securities Act or any rule or regulation promulgated thereunder
applicable to the Company and relating to action or inaction required of the Company in connection with any such registration; and the
Company shall promptly reimburse the Investor Indemnified Party for any legal and any other expenses reasonably incurred by such Investor
Indemnified Party in connection with investigating and defending any such expense, loss, judgment, claim, damage, liability or action;
provided, however, that the Company will not be liable in any such case to the extent that any such expense, loss, claim,
damage or liability arises out of or is based upon any untrue statement or allegedly untrue statement or omission or alleged omission
made in such Registration Statement, preliminary prospectus, final prospectus, or summary prospectus, or any such amendment or supplement,
in reliance upon and in conformity with information furnished to the Company, in writing, by such selling holder expressly for use therein,
or is based on any selling holder’s violation of the federal securities laws (including Regulation M) or failure to sell the Registrable
Securities in accordance with the plan of distribution contained in the prospectus.

 

4.2
Indemnification by Holders of Registrable Securities. Each selling holder of Registrable Securities will, in the event that any
Registration is being effected under the Securities Act pursuant to this Agreement of any Registrable Securities held by such selling
holder, indemnify and hold harmless the Company, each of its directors and officers, and each other selling holder and each other person,
if any, who controls another selling holder within the meaning of the Securities Act, against any losses, claims, judgments, damages
or liabilities, whether joint or several, insofar as such losses, claims, judgments, damages or liabilities (or actions in respect thereof)
arise out of or are based upon any untrue statement or allegedly untrue statement of a material fact contained in any Registration Statement
filed pursuant to this Agreement under which the sale of such Registrable Securities was registered under the Securities Act, any preliminary
prospectus, final prospectus or summary prospectus contained in the Registration Statement, or any amendment or supplement to the Registration
Statement, or arise out of or are based upon any omission or the alleged omission to state a material fact required to be stated therein
or necessary to make the statement therein not misleading, if the statement or omission was made in reliance upon and in conformity with
information furnished in writing to the Company by such selling holder expressly for use therein, or is based on any selling holder’s
violation of the federal securities laws (including Regulation M) or failure to sell the Registrable Securities in accordance with the
plan of distribution contained in the prospectus, and shall reimburse the Company, its directors and officers, and each other selling
holder or controlling person for any legal or other expenses reasonably incurred by any of them in connection with investigation or defending
any such loss, claim, damage, liability or action. Each selling holder’s indemnification obligations hereunder shall be several
and not joint and shall be limited to the amount of any net proceeds actually received by such selling holder.

 

4.3
Conduct of Indemnification Proceedings. Promptly after receipt by any person of any notice of any loss, claim, damage or liability
or any action in respect of which indemnity may be sought pursuant to Sections 4.1 or 4.2, such person (the “Indemnified
Party”) shall, if a claim in respect thereof is to be made against any other person for indemnification hereunder, notify such
other person (the “Indemnifying Party”) in writing of the loss, claim, judgment, damage, liability or action; provided,
however, that the failure by the Indemnified Party to notify the Indemnifying Party shall not relieve the Indemnifying Party from
any liability which the Indemnifying Party may have to such Indemnified Party hereunder, except and solely to the extent the Indemnifying
Party is actually prejudiced by such failure. If the Indemnified Party is seeking indemnification with respect to any claim or action
brought against the Indemnified Party, then the Indemnifying Party shall be entitled to participate in such claim or action, and, to
the extent that it wishes, jointly with all other Indemnifying Parties, to assume control of the defense thereof with counsel satisfactory
to the Indemnified Party. After notice from the Indemnifying Party to the Indemnified Party of its election to assume control of the
defense of such claim or action, the Indemnifying Party shall not be liable to the Indemnified Party for any legal or other expenses
subsequently incurred by the Indemnified Party in connection with the defense thereof other than reasonable costs of investigation; provided,
however, that in any action in which both the Indemnified Party and the Indemnifying Party are named as defendants, the Indemnified
Party shall have the right to employ separate counsel (but no more than one such separate counsel, which counsel is reasonably acceptable
to the Indemnifying Party) to represent the Indemnified Party and its controlling persons who may be subject to liability arising out
of any claim in respect of which indemnity may be sought by the Indemnified Party against the Indemnifying Party, with the fees and expenses
of such counsel to be paid by such Indemnifying Party if, based upon the written opinion of counsel of such Indemnified Party, representation
of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. No Indemnifying
Party shall, without the prior written consent of the Indemnified Party, consent to entry of judgment or effect any settlement of any
claim or pending or threatened proceeding in respect of which the Indemnified Party is or could have been a party and indemnity could
have been sought hereunder by such Indemnified Party, unless such judgment or settlement includes an unconditional release of such Indemnified
Party from all liability arising out of such claim or proceeding.

 

    	9

    	 

    

 

4.4
Contribution.

 

4.4.1
If the indemnification provided for in the foregoing Sections 4.1, 4.2 and/or 4.3 is unavailable to any Indemnified
Party in respect of any loss, claim, damage, liability or action referred to herein, then each such Indemnifying Party, in lieu of indemnifying
such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, claim, damage,
liability or action in such proportion as is appropriate to reflect the relative fault of the Indemnified Parties and the Indemnifying
Parties in connection with the actions or omissions which resulted in such loss, claim, damage, liability or action, as well as any other
relevant equitable considerations. The relative fault of any Indemnified Party and any Indemnifying Party shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by such Indemnified Party or such Indemnifying Party and the parties’ relative
intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

 

4.4.2
The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 4.4 were determined
by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in
Section 4.4.1.

 

4.4.3
The amount paid or payable by an Indemnified Party as a result of any loss, claim, damage, liability or action referred to in the immediately
preceding paragraph shall be deemed to include, subject to the limitations set forth above in Section 4.4.1, any legal or other
expenses incurred by such Indemnified Party in connection with investigating or defending any such action or claim. Notwithstanding the
provisions of this Section 4.4, no holder of Registrable Securities shall be required to contribute any amount in excess of the
dollar amount of the net proceeds (after payment of any underwriting fees, discounts, commissions or taxes) actually received by such
holder from the sale of Registrable Securities which gave rise to such contribution obligation. No person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation.

 

5.
UNDERWRITING AND DISTRIBUTION. 

 

5.1
Rule 144. As long as any Holder shall own Registrable Securities, the Company, at all times while it shall be a reporting company
under the Exchange Act, covenants that it shall (i) file (or obtain extensions in respect thereof and file within the applicable grace
period) any reports required to be filed by it after the date hereof pursuant to Section 13(a) or 15(d) of the Exchange Act and to promptly
furnish such Holders with true and complete copies of all such filings (which shall include providing notice that such filings are available
on the SEC’s website at www.sec.gov or the Company’s website within two days of such filing), and (ii) take such further
action as the holders of Registrable Securities may reasonably request, all to the extent required from time to time to enable such holders
to sell Registrable Securities without registration under the Securities Act within the limitation of the exemptions provided by Rule
144 under the Securities Act, as such rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the
Commission. Upon the request of any Holder, the Company will deliver to such Holder a written statement of a duly authorized officer
as to whether the Company has complied with such information requirements, and, if not, the specific reasons for non-compliance.

 

6.
MISCELLANEOUS. 

 

6.1
Other Registration Rights and Arrangements. The Company represents and warrants that no person, other than a holder of the Registrable
Securities has any right to require the Company to register any of the Company’s share capital or capital shares for sale or to
include the Company’s share capital or capital shares in any registration filed by the Company for the sale of shares for its own
account or for the account of any other person. The Company shall not hereafter enter into any agreement with respect to its securities
which is inconsistent with or violates the rights granted to the holders of Registrable Securities in this Agreement and in the event
of any conflict between any such agreement or agreements and this Agreement, the terms of this Agreement shall prevail.

 

    	10

    	 

    

 

6.2
Assignment; No Third-Party Beneficiaries. This Agreement and the rights, duties and obligations of the Company hereunder may not
be assigned or delegated by the Company in whole or in part. This Agreement and any of the rights, duties and obligations of the holders
of Registrable Securities hereunder may be freely assigned or delegated, in whole or in part, by such holder of Registrable Securities
in conjunction with and to the extent of any transfer of any Registrable Security by any such holder to a Permitted Transferee(s). This
Agreement and the provisions hereof shall be binding upon and shall inure to the benefit of each of the parties hereto and their respective
successors and assigns and the holders of Registrable Securities and their respective successors and permitted assigns. This Agreement
is not intended to confer any rights or benefits on any persons that are not party hereto other than as expressly set forth in Section
4 and this Section 6.2. The rights of a holder of Registrable Securities under this Agreement may be transferred, in whole
or in part, by such a holder to a Permitted Transferee who acquires or holds any Registrable Security; provided, however,
that such transferee has executed and delivered to the Company a properly completed agreement to be bound by the terms of this Agreement
substantially in form attached hereto as Exhibit A (a “Joinder”), and the transferor shall have delivered to
the Company no later than five (5) Business Days following the date of the transfer, written notification of such transfer setting forth
the name of the transferor, the name and address of the Permitted Transferee, and the number of Registrable Securities so transferred.
The execution of a Joinder shall constitute a permitted amendment of this Agreement.

 

6.3
Amendments and Modifications. Upon the written consent of the Company and the holders of at least a majority in interest of the
Registrable Securities at the time in question, compliance with any of the provisions, covenants and conditions set forth in this Agreement
may be waived, or any of such provisions, covenants or conditions may be amended or modified; provided, however, that notwithstanding
the foregoing, any amendment hereto or waiver hereof that adversely affects an Investor, solely in his, her or its capacity as a holder
of the securities of the Company, in a manner that is materially different from other Investors (in such capacity) shall require the
consent of such Investor so affected. No course of dealing between any Investor or the Company and any other party hereto or any failure
or delay on the part of an Investor or the Company in exercising any rights or remedies under this Agreement shall operate as a waiver
of any rights or remedies of any Investor or the Company. No single or partial exercise of any rights or remedies under this Agreement
by a party shall operate as a waiver or preclude the exercise of any other rights or remedies hereunder or thereunder by such party.

 

6.4
Term. This Agreement shall terminate upon the earlier of (i) the fifth anniversary of the date of this Agreement or (ii) the date
as of which there shall be no Registrable Securities outstanding; provided that with respect to any Investor, such Investor will have
no rights under this Agreement and all obligations of the Company to such Investor under this Agreement shall terminate upon the date
that such Investor no longer holds Registrable Securities.

 

6.5
Notices. All notices, requests, demands, waivers and other communications hereunder shall be in writing and shall be deemed to
have been duly given (a) when delivered in person or by e-mail, (b) on the next Business Day when sent by overnight courier or (c) on
the second (2nd) succeeding Business Day when sent by registered or certified mail (postage prepaid, return receipt requested) to the
respective Parties at the following addresses (or at such other address for a Party as shall be specified by like notice):

 

If
to the Company:

 

Flexible
Solutions International Inc.

6001
54th Ave.

Taber,
Alberta, Canada T1G 1X4

Attn:
Chief Executive Officer

 

with
a copy to:

 

Orrick,
Herrington & Sutcliffe LLP

 

    	11

    	 

    

 

The
Orrick Building

405
Howard Street

San
Francisco, CA 94105

Attention:
Richard Smith

Albert
Vanderlaan

E-mail:
rsmith@orrick.com

avanderlaan@orrick.com

 

If
to an Investor, to the address set forth under such Investor’s signature to this Agreement or to such Investor’s address
as found in the Company’s books and records.

 

All
such notices, requests, demands, waivers and other communications shall be deemed received upon (i) actual receipt thereof by the addressee,
or (ii) actual delivery thereof to the appropriate address.

 

6.6
Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule
of Law or public policy, all other terms, conditions and provisions of this Agreement shall nevertheless remain in full force and effect
so long as the economic or legal substance of the transactions contemplated by this Agreement is not affected in any manner materially
adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the
parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible
in a mutually acceptable manner in order that the transactions contemplated by this Agreement be consummated as originally contemplated
to the fullest extent possible.

 

6.7
Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which
taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement
by facsimile or e-mail shall be as effective as delivery of a manually executed counterpart of the Agreement. Minor variations in the
form of the signature page, including footers from earlier versions of this Agreement or any such other document, will be disregarded
in determining a Party’s intent or the effectiveness of such signature.

 

6.8
Entire Agreement. This Agreement (including all agreements entered into pursuant hereto and all certificates and instruments delivered
pursuant hereto and thereto) constitute the entire agreement among the parties with respect to the subject matter of this Agreement and
supersede all other prior agreements and understandings, both written and oral, between the parties with respect to the subject matter
of this Agreement, including without limitation, the Prior Agreement. Each party acknowledges and agrees that, in entering into this
Agreement, such party has not relied on any promises or assurances, written or oral, that are not reflected in this Agreement (including
the Schedules and Exhibits attached hereto).

 

6.9
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware (regardless
of the laws that might otherwise govern under applicable principles of conflicts of laws thereof) as to all matters (including Actions
related hereto), including matters of validity, construction, effect, performance and remedies.

 

    	12

    	 

    

 

6.10
Consent to Jurisdiction; Etc.. Each party hereby agrees, and any Person asserting rights as a third party beneficiary may do so
only if he, she or it irrevocably agrees, that any Legal Dispute shall be brought only to the exclusive jurisdiction of the courts of
the State of Delaware or the federal courts located in the State of Delaware, and each party hereby consents to the jurisdiction of such
courts (and of the appropriate appellate courts therefrom) in any such Action and irrevocably waives, to the fullest extent permitted
by law, any objection that it may now or hereafter have to the laying of the venue of any such Action in any such court or that any such
Action that is brought in any such court has been brought in an inconvenient forum. During the period a Legal Dispute that is filed in
accordance with this Section 6.10 is pending before a court, all Actions with respect to such Legal Dispute or any other Legal Dispute,
including any counterclaim, cross-claim or interpleader, shall be subject to the exclusive jurisdiction of such court. Each party hereby
waives, and any person asserting rights as a third party beneficiary may do so only if he, she or it hereby waives, and shall not assert
as a defense in any Legal Dispute, that (a) such party is not personally subject to the jurisdiction of the above named courts for any
reason, (b) such Action may not be brought or is not maintainable in such court, (c) such party’s property is exempt or immune
from execution, (d) such Action is brought in an inconvenient forum, or (e) the venue of such Action is improper. A final judgment in
any Action described in this Section 6.10 following the expiration of any period permitted for appeal and subject to any stay
during appeal shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided
by applicable laws.

 

6.11
WAIVER OF JURY TRIAL. EACH OF THE PARTIES HEREBY UNCONDITIONALLY WAIVES, AND ANY PERSON ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY
MAY DO SO ONLY IF HE, SHE OR IT IRREVOCABLY AND UNCONDITIONALLY WAIVES, ANY RIGHT TO TRIAL BY JURY ON ANY CLAIMS OR COUNTERCLAIMS ASSERTED
IN ANY LEGAL DISPUTE RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY AND FOR ANY COUNTERCLAIM RELATING THERETO. IF
THE SUBJECT MATTER OF ANY SUCH LEGAL DISPUTE IS ONE IN WHICH THE WAIVER OF JURY TRIAL IS PROHIBITED, NO PARTY NOR ANY PERSON ASSERTING
RIGHTS AS A THIRD PARTY BENEFICIARY SHALL ASSERT IN SUCH LEGAL DISPUTE A NONCOMPULSORY COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. FURTHERMORE, NO PARTY NOR ANY PERSON ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY
SHALL SEEK TO CONSOLIDATE ANY SUCH LEGAL DISPUTE WITH A SEPARATE ACTION OR OTHER LEGAL PROCEEDING IN WHICH A JURY TRIAL CANNOT BE WAIVED.

 

[Signature
pages follow]

 

    	13

    	 

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed and delivered by their duly authorized representatives as
of the date first written above.

 

	 	COMPANY:
    FLEXIBLE SOLUTIONS INTERNATIONAL INC.
	 	 	 
	 	By:	/s/
    John Bientjes
	 	Name:	John Bientjes
	 	Title:	Director,
    Audit Committee Chair and Compensation Committee Member

 

    	14

    	 

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed and delivered by their duly authorized representatives as
of the date first written above.

 

	 	INVESTOR:
	 	 	 
	 	By:	/s/
    Daniel B. O’Brien
	 	 	 
	 	Name:	Daniel
    B. O’Brien

 

    	15

    	 

    

 

EXHIBIT
A

 

Joinder

 

This
Joinder (“Joinder”) is executed on ________, 20__, by the undersigned (the “New Holder”) pursuant
to the terms of that certain Registration Rights Agreement dated as of [•], 2022 (the “Agreement”), by and among
Flexible Solutions International Inc., an Alberta, Canada corporation (including any of its successors or assigns, the “Company”),
and the Investors identified therein, as such Agreement may be amended, supplemented or otherwise modified from time to time. Capitalized
terms used but not defined in this Joinder shall have the respective meanings ascribed to such terms in the Agreement. By the execution
of this Joinder, the New Holder agrees as follows:

 

1.
Acknowledgment. New Holder acknowledges that New Holder is acquiring certain equity securities of the Company (the “Shares”)
as a transferee of such Shares from a party in such party’s capacity as a holder of Registrable Securities under the Agreement,
and after such transfer, New Holder shall be considered an “Investor” and a holder of Registrable Securities for all purposes
under the Agreement.

 

2.
Agreement. New Holder hereby (a) agrees that the Shares shall be bound by and subject to the terms of the Agreement and (b) adopts
the Agreement with the same force and effect as if the New Holder were originally a party thereto.

 

3.
Notice. Any notice required or permitted by the Agreement shall be given to New Holder at the address or facsimile number listed
below New Holder’s signature below.

 

	NEW
    HOLDER:	 	 	 	ACCEPTED
    AND AGREED:
	 	 	 	 	 
	Print
    Name:	 	 	 	 	 	COMPANY	 	 
	 	 	 	 	 
	By:	 	 	 	 	 	By:	 	 
	 	 	 	 	 
	Address:	 	 	 	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 	 	 	 	 

 

    	16

    	 

    

 

SCHEDULE
A

 

INVESTORS:

 

Daniel
B. O’Brien

 

    	17EXHIBIT
10.2

 

EMPLOYMENT
AGREEMENT

 

This
Employment Agreement (the “Agreement”) is entered into as of the 17th day of April 2022, between Daniel
O’Brien (the “Executive”) and Flexible Solutions International, Inc. (the “Company”).

 

RECITALS

 

WHEREAS,
the Company and Lygos, Inc. (“Lygos”) intend to enter into an Agreement and Plan of Merger and Reorganization by and
between the Company, Lygos and those certain other parties identified therein (the “Merger Agreement”) whereby Lygos
will merge with and into a wholly owned subsidiary of the Company (the “Merger”); and

 

WHEREAS,
in connection with the Merger, the Company desires to enter into this Agreement with Executive, effective as of the closing of the Merger
(the actual date of closing, the “Closing Date”).

 

NOW,
THEREFORE, in consideration of the mutual covenants contained herein and other valid consideration, the sufficiency of which is acknowledged,
the Company and Executive agree as follows:

 

AGREEMENT

 

1. Employment;
Devotion to Duties.

 

(a) General.
The Company will employ Executive as its Head-Flexible Solutions Division reporting to the Company’s Board of Directors (the “Board”),
and Executive accepts employment to serve in this capacity, all upon the terms and conditions in this Agreement.

 

(b) Devotion
to Duties. During the Term, Executive will devote as much of his business time and efforts to the performance of his duties on
the Company’s behalf as the Executive believes are needed.

 

2. Term.

 

Executive
will begin employment under the terms of this Agreement starting on the Closing Date (the “Commencement Date”). Executive
will be employed under this Agreement until five years after the Commencement Date (the “Term”).

 

3. Location.
The location of Executive’s principal place of employment will be at the Executive’s residence in Victoria, Canada. However,
the Executive understands that he may be required to travel and perform services outside of this area as reasonably required to properly
perform his duties under this Agreement.

 

    	 	 	 

     

    

 

4. Compensation.

 

(a) Base
Salary. The Company will pay Executive an annual base salary (“Base Salary”) in the amount of $500,000, subject
to future modification in accordance with the Company’s Executive compensation review policies and practices. The Base Salary will
be adjusted annually based upon any increase in the Consumer Price Index during each twelve month anniversary of the Commencement Date.
The Base Salary will be paid in accordance with the Company’s payroll practices in effect from time to time.

 

(b)
Option and Share Grants.

 

(i)
On the Commencement Date, the Company will grant to the Executive options to purchase 500,000 shares of the Company’s common stock
pursuant to the FSI 2022 Equity Incentive Plan. The options will expire seven years after the grant date and will vest and become exercisable
on the twelve-month anniversary of the grant date. The options will be exercisable at a price of $6.00 per share provided however
that if the Company, during the twelve-month period following the grant date, grants any person an option with an exercise price
less than $6.00 per share, then the exercise price of the options held by the Executive will be lowered to the lowest exercise
price of any option granted during such twelve-month period. The exercise price per share will in no event be lower than the fair
market value per share on the date the options are granted or, if applicable, the date the options are subsequently repriced, in each
case, as determined by the Board in good faith. Executive should consult with Executive’s own tax advisor concerning the tax risks
associated with accepting an option to purchase a share of the Company’s common stock.

 

(ii)
Twenty months after the Commencement Date, the Company will issue 1,000,000 shares of its common stock to the Executive as a stock grant.2
The shares will be issued even if the Executive is not then employed by the Company. The shares will be fully vested, and will
not be subject to cancellation or forfeiture.

 

(iii)
Thirty months after the Commencement Date, the Company will issue 1,000,000 shares of its common stock to the Executive as a stock grant.
The shares will be issued even if the Executive is not then employed by the Company. The shares will be fully vested, and will not be
subject to cancellation or forfeiture.

 

(iv)
The shares issuable to the Executive upon the exercise of the options and the shares issued to the Executive as a stock grant will be
registered by means of a registration statement on Form S-8 that the Company will file with the Securities and Exchange Commission.

 

(c) Stock
Purchase. On the Commencement Date the Company, and/or persons designated by the Company, will purchase 1,000,000 shares of the
Company’s common stock owned by the Executive at a price of $7.50 per share.

 

 

2
NTD: The stock grants cannot be made under the Equity Incentive Plan if the Executive is no longer providing services to the Company
(i.e., they would have to be granted outside the plan). 

 

    	 	-2-	 

     

    

 

5. Executive
Benefits.

 

(a) Fringe
Benefits; Paid Time Off. The Company will not provide Executive with those fringe benefits and other Executive benefits on the
same terms and conditions as generally available to senior management from time to time (e.g., health and other insurance programs,
etc.); provided, however, that the Company reserves the right to amend or terminate any employee or Executive benefit plan or program.
Executive is entitled to paid time off (PTO) during each calendar year, with the amount and scheduling of the vacation to be determined
under the Company’s PTO policies as in effect from time to time.

 

(b) Reimbursement
of Expenses. Executive is entitled to be reimbursed by the Company for reasonable business expenses incurred in performing his
duties under the Company’s expense reimbursement policies as in effect from time to time or as otherwise approved by the Company’s
Chief Executive Officer or the Board.

 

6. Termination
of Employment During the Term of the Agreement. Upon, and as of, the date of the Executive’s termination of employment
with the Company for any reason, the Executive will be deemed to have resigned from all positions he then holds as an officer or employee
of the Company. All stock options which Executive holds at the time of such termination shall become fully vested. The Executive’s
employment may be terminated during the Term of this Agreement pursuant to the following terms and conditions:

 

(a) Company
Terminates Executive’s Employment for Cause.

 

(i) Definition.
For purposes of this Agreement, Cause means (A) the Executive’s failure to substantially perform his reasonably assigned duties
(other than on account of Disability); (B) the Executive is convicted of criminal conduct having the effect of materially adversely affecting
the Company, after all rights of appeal have expired or such appeals have been exhausted; (C) the Executive engages in the use of alcohol
or narcotics to the extent that the performance of his duties is materially impaired; (D) the Executive materially breaches the terms
of this Agreement; (E) the Executive engages in willful misconduct that is materially injurious to the Company, other than business decisions
made in good faith; or (F) the Executive commits any act or omission not described above that constitutes material and willful misfeasance,
malfeasance, fraud or gross negligence in the performance of his duties to the Company.

 

(ii) Effective
Date of Termination. Executive’s employment will terminate immediately upon written notice by the Company to Executive
stating that Executive’s employment is being terminated for Cause.

 

(iii) Compensation
and Benefits. If the Company terminates the Executive’s employment for Cause, the Company will pay Executive (A) any earned
but unpaid Base Salary through the effective date of termination, and (B) any other unpaid benefit to which he has earned under the applicable
terms of any applicable plan, program, agreement or arrangement of the Company or its affiliates (the amounts in (A) and (B) above are
referred to elsewhere in this Agreement as “Accrued Amounts”).

 

    	 	-3-	 

     

    

 

(b) Company
Terminates Executive’s Employment without Cause.

 

(i) Effective
Date of Termination. Executive’s employment will terminate on the earlier of the (x) last day of the Term, or (y) 30th
day after the Company gives written notice to Executive stating that Executive’s employment is being terminated without Cause.
The Company may, at its discretion, place Executive on a paid administrative leave during all or any part of the notice period. During
the administrative leave, the Company may bar Executive’s access to its offices or facilities or may provide Executive with access
subject to such terms and conditions as the Company chooses to impose. For the avoidance of doubt, the expiration of the Term in accordance
with Section 2 above will not constitute a termination without Cause.

 

(c) Executive
Voluntarily Resigns.

 

(i) Effective
Date of Termination. Executive’s employment will terminate on the earlier of the (x) last day of the Term, or (y) 30th
day after Executive gives written notice to the Company stating that Executive is resigning his employment with the Company for any reason,
unless the Company waives in writing all or part of this notice period (in which case the termination of employment is effective as of
the date of the waiver).

 

(ii) Compensation
and Benefits. If the Executive voluntarily resigns, the Company will pay Executive the Accrued Amounts.

 

(d) Disability.

 

(i) Definition.
For purposes of this Agreement, Disability or Disabled means the Executive (A) is unable to engage in any substantial gainful activity
by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last
for a continuous period of not less than 12 months, or (B) is, by reason of any medically determinable physical or mental impairment
that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, is receiving income
replacement benefits for a period of not less than three months under an accident and health plan covering the Company’s employees.

 

(ii) Effective
Date of Termination. Executive’s employment will terminate on the first day the Company makes a determination that the
Executive is Disabled.

 

(iii) Compensation
and Benefits. Upon a determination that the Executive is Disabled, the Company will pay to Executive any Accrued Amounts, plus
a lump sum equal to one month of Executive’s then Base Salary, reduced by any disability insurance maintained by the Company to
be received by Executive for 6 months following his termination of employment, payable within 30 days following the date of Executive’s
termination of employment.

 

(e) Death.

 

(i) Effective
Date of Termination. Executive’s employment will terminate immediately upon the Executive’s death.

 

    	 	-4-	 

     

    

 

(ii) Compensation
and Benefits. If the Executive dies during the Term, the Company will pay Executive’s designated beneficiary, or his estate
if there is no designated beneficiary, the Accrued Amounts. Any amounts payable under this Section 7(e)(ii) are in addition to
any payments which the Executive’s designated beneficiary or estate may be entitled to receive pursuant to any pension plan, profit
sharing plan, employee benefit plan, or life insurance policy maintained by the Company.

 

(f) Other
Termination.

 

(i) Compensation
and Benefits. If the Executive resigns for Good Reason in connection with or within a period of 12 months following a Change
in Control, the Company terminates Executive’s employment pursuant to Section 6(b) of this Agreement, or the Executive terminates
his employment for Good Reason, then, in addition to the Accrued Amounts, and subject to Section 8 below:

 

	 	●	The
    Company will pay to Executive all amounts due to Executive pursuant to this Agreement, plus three months of Executive’s then
    current Base Salary.
	 	 	 
	 	●	the
    Company will (a) fully accelerate the vesting of any then-unvested stock options held by the Executive and (b) extend the post-termination
    exercise period until the expiration date of the stock options held by the Executive; 3
	 	 	 
	 	●	to
    the extent permissible under the terms of the Company’s welfare benefit plans, the continuation of all Company welfare benefits,
    including medical, dental, vision, life and disability benefits pursuant to plans maintained by the Company under which the Executive
    and/or the Executive’s family were receiving benefits and/or coverage, or otherwise reimburse Executive for the cost of continuation
    of state health coverage for the Executive and/or the Executive’s family, for the 18-month period following the date of the
    Executive’s termination, and the Executive shall pay any portion of such cost as was required to be borne by key Executives
    of the Company generally on the date of termination; provided, however, that, the coverage for any plan subject to COBRA or state
    continuation of coverage will discontinue if such coverage terminates under Section 4980B of the Code.

 

For
purposes of this Agreement, the term Change in Control means (A) the sale of 50% or more of the outstanding voting securities of the
Company in a single transaction or a series of transaction occurring during a twelve-month period; (B) A majority of the members of the
Board of Directors is replaced during any twelve-month period by directors whose appointment or election is not endorsed by a majority
of the Company’s Board of Directors prior to the date of the appointment or election; (C) the Company is merged or consolidated
with another corporation and as a result of such merger or consolidation less than 50% of the outstanding securities of the surviving
or resulting corporation is owned in the aggregate by the shareholders of the Company that existed immediately prior the merger or consolidation;
(D) the Company sells more than 40% of the fair market value of its assets to another corporation that is not a wholly owned subsidiary
of the Company during a twelve-month period or (E) the acquisition by any individual, entity or group having beneficial ownership (within
the meaning of Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) of 50% or more of the Company’s either
(1) the then outstanding shares of common stock of the Company or (2) the combined voting power of the then outstanding voting securities
of the Company entitled to vote in the election of directors. For the avoidance of doubt, the Merger will not constitute a Change in
Control for purposes of this Agreement.

 

 

3
NTD: Under Section 409A, the expiration date cannot be extended. We can however extend the post-termination exercise period, which
we assume is what was intended. 

 

    	 	-5-	 

     

    

 

For
purposes of this Agreement, “Good Reason” means assigning the Executive to any duties that are materially inconsistent
with his position as described in Section 1, a reduction of Executive’s Base Salary without the prior written consent of
the Executive, or a relocation of Executive’s primary job duties to a location more than 50 miles from the location described in
Section 3; provided, however, occasional business travel in accordance with Section 3 will not constitute Good Reason. The foregoing
notwithstanding, a condition is not considered “Good Reason” unless (A) Executive gives the Company written notice
of such condition within 30 days after the condition comes into existence; (B) the Company fails to cure the condition within 30 days
after receiving Executive’s written notice; and (C) Executive terminates his employment within 12 months following a Change in
Control.

 

(ii) Change
in Control Payment/Section 280G Limitation.

 

(1) General
Rules. Code Sections 280G and 4999 may place significant tax burdens on both Executive and the Company if the total payments
made to Executive due to certain change in control events described in Code Section 280G (the “Total Change in Control Payments”)
equal or exceed the 280G Cap (three times the Executive’s “Base Amount” as defined in Code Section 280G). If
the Total Change in Control Payments equal or exceed the 280G Cap, Section 4999 of the Code imposes a 20% excise tax (the “Excise
Tax”) on all amounts in excess of one times Executive’s Base Period Income Amount. The Excise Tax is imposed on Executive,
rather than the Company, and will be withheld by the Company from any amounts payable to Executive pursuant to this Agreement. In determining
whether the Total Change in Control Payments will exceed the 280G Cap and result in an Excise Tax becoming due, and for purposes of calculating
the 280G Cap itself, the provisions of Code Sections 280G and 4999 and the applicable regulations will control over the general provisions
of this Section 6(f)(iii).

 

(2) Limitation
on Payments. Subject to the “best net” exception described in Section 6(f)(ii)(3) below, in order to avoid
the imposition of the Excise Tax, the total payments to which Executive is entitled under this Agreement or otherwise will be reduced
to the extent necessary to avoid exceeding the 280G Cap minus $1.00.

 

(3) ”Best
Net” Exception. If Executive’s Total Change in Control Payments minus the Excise Tax payable on all such payments
exceeds the 280G Cap minus $1.00, then the total payments to which Executive is entitled under this Agreement or otherwise will not be
reduced pursuant to Section 6(f)(ii)(2). If the “best net” exception applies, Executive shall be responsible for paying
any Excise Tax (and income or other taxes) that may be imposed on Executive pursuant to Code Section 4999 or otherwise.

 

    	 	-6-	 

     

    

 

(4) Calculating
the 280G Cap. If the Company believes that the provisions of Section 6(f)(ii)(2) may apply to reduce the total payments
to which Executive is entitled under this Agreement or otherwise, it will notify Executive as soon as possible. The Company then will
engage a “Consultant” (a law firm, a certified public accounting firm, and/or a firm of recognized Executive compensation
consultants) to make any necessary determinations and to perform any necessary calculations required in order to implement the rules
set forth in this Section 6. The Consultant shall provide detailed supporting calculations to both the Company and Executive and
all fees and expenses of the Consultant shall be borne by the Company.

 

If
the Consultant determines that the limitations of Section 6(f)(ii)(2) apply, then the total payments to which Executive is entitled
under this Agreement or otherwise will be reduced to the extent necessary to eliminate the amount in excess of the 280G Cap. Such payments
will be made at the times specified herein, in the maximum amount that may be paid without exceeding the 280G Cap. The balance, if any,
will then be paid, if due, after the opinions called for by Section 6 have been received.

 

If
the amount paid to Executive by the Company is ultimately determined by the Internal Revenue Service to have exceeded the limitations
of Section 6(f)(ii)(2), Executive must repay the excess promptly on demand of the Company. If it is ultimately determined by the
Consultant or the Internal Revenue Service that a greater payment should have been made to Executive, the Company shall pay Executive
the amount of the deficiency within 30 days of such determination.

 

As
a general rule, the Consultant’s determination shall be binding on Executive and the Company. Section 280G and the Excise Tax rules
of Section 4999, however, are complex and uncertain and, as a result, the Internal Revenue Service may disagree with the Consultant’s
conclusions. If the Internal Revenue Service determines that the 280G Cap is actually lower than calculated by the Consultant, the 280G
Cap will be recalculated by the Consultant. Any payment in excess of the revised 280G Cap then will be repaid by Executive to the Company.
If the Internal Revenue Service determines that the actual 280G Cap exceeds the amount calculated by the Executive, the Company shall
pay Executive any shortage.

 

The
Company has the right to challenge any determinations made by the Internal Revenue Service. If the Company agrees to indemnify Executive
from any taxes, interest and penalties that may be imposed on Executive in connection with such challenge, then Executive must cooperate
fully with the Company. the Company shall bear all costs associated with the challenge of any determination made by the Internal Revenue
Service and the Company shall control all such challenges.

 

Executive
must notify the Company in writing of any claim or determination by the Internal Revenue Service that, if upheld, would result in the
payment of Excise Taxes. Such notice shall be given as soon as possible but in no event later than 15 days following Executive’s
receipt of the notice of the Internal Revenue Service’s position.

 

(5) Effect
of Repeal. If the provisions of Code Sections 280G and 4999 are repealed without succession, this Section 6(f)(ii) will
not apply. In addition, if this provision does not apply to Executive for whatever reason (e.g., because Executive is not a “disqualified
individual” for purposes of Code Section 280G), this Section will not apply.

 

    	 	-7-	 

     

    

 

(h) Compliance
with Code Section 409A. Any payment under this Section 6 is subject to the provisions of this Section 6(h) (except
for a payment pursuant to Disability or death under Section 6(d) or (e)). If Executive is a “Specified Employee”
of the Company for purposes of Code Section 409A at the time of a payment event in Section 6(b) and if no exception from Code
Section 409A applies in whole or in part, the severance or other payments will be made to Executive by the Company on the first day of
the seventh month following the date of the Executive’s Separation from Service (the “409A Payment Date”). Should
this Section 6(h) result in a delay of payments to Executive, the Company will begin to make the payments as described in this
Section 6, provided that any amounts that would have been payable earlier but for the application of this Section 6(h),
will be paid in lump-sum on the 409A Payment Date along with accrued interest at the rate of interest announced by the Company’s
primary bank from time to time as its prime rate from the date that payments would otherwise have been made under this Agreement. The
balance of the severance payments will be payable in accordance with regular payroll timing and the COBRA premiums will be paid monthly.
For purposes of the provision, the term Specified Employee has the meaning in Code Section 409A(a)(2)(B)(i), or any successor provision
and the issued treasury regulations and rulings. “Separation from Service” or “Termination of Employment”
means, with respect to any payment that is subject to Code Section 409A, either (a) termination of Executive’s employment with
Company and all affiliates, or (b) a permanent reduction in the level of bona fide services Executive provides to Company and all affiliates
to an amount that is 20% or less of the average level of bona fide services Executive provided to Company in the immediately preceding
36 months, with the level of bona fide service calculated in accordance with Treasury Regulations Section 1.409A-1(h)(1)(ii). Solely
for purposes of determining whether Executive has a “Separation from Service,” Executive’s employment relationship
is treated as continuing while Executive is on military leave, sick leave, or other bona fide leave of absence (if the period of such
leave does not exceed six months, or if longer, so long as Executive’s right to reemployment with Company or an affiliate is provided
either by statute or contract). If Executive’s period of leave exceeds six months and Executive’s right to reemployment is
not provided either by statute or by contract, the employment relationship is deemed to terminate on the first day immediately following
the expiration of such six-month period. Whether a termination of employment has occurred will be determined based on all of the facts
and circumstances and in accordance with regulations issued by the United States Treasury Department pursuant to Code Section 409A. If
the payment is not subject to Code Section 409A, the term termination of employment will be given its ordinary meaning.

 

(i) Mitigation/Offset.
The Executive is under no obligation to seek other Employment or to otherwise mitigate the obligations of the Company under this Agreement,
and the Company may not offset against amounts or benefits due Executive under this Agreement or otherwise on account of any claim (other
than any preexisting debts then due in accordance with their terms) the Company or its affiliates may have against him or any remuneration
or other benefit earned or received by Executive after such termination.

 

    	 	-8-	 

     

    

 

7. Executive’s
Other Obligations.

 

(a) Confidentiality
Agreement. Executive’s acceptance of this Agreement and Executive’s employment with the Company is contingent upon
the execution, and delivery to an officer of the Company, of the Company’s Confidential Information and Invention Assignment Agreement,
a copy of which is attached hereto as Attachment A for Executive’s review and execution (the “Confidentiality Agreement”),
prior to or on Executive’s Commencement Date.

 

(b) Survival.
The provisions of this Section 7 survive the termination of this Agreement.

 

(c) Cooperation;
No Disparagement. Following the Termination of this Agreement, for whatever reason, Executive agrees to provide reasonable assistance
to the Company (including assistance with litigation matters), upon the Company’s request, concerning the Executive’s previous
employment responsibilities and functions with the Company. In consideration for such cooperation, but only if the Executive is not receiving
severance pursuant to this Agreement, Company will compensate Executive for the time Executive spends on such cooperative efforts (at
an hourly rate based on Executive’s Base Salary during the year preceding the date of termination) and Company will reimburse Executive
for his reasonable out-of-pocket expenses Executive incurs in connection with such cooperative efforts. Additionally, at all times after
the Executive’s employment with the Company has terminated, Company (defined for this purpose only as any Company press release
and the Board, the CEO and the CEO’s direct reports, and no other employees) and Executive agree to refrain from making any disparaging
or derogatory remarks, statements and/or publications regarding the other, its employees or its services.

 

8. General
Provisions.

 

(a) Severability.
If any provision of this Agreement is held to be illegal, invalid, or unenforceable under any applicable law, then, if legally permissible,
such provision will be deemed to be modified to the extent necessary to render it legal, valid and enforceable, and if no modification
will make the provision legal, valid and enforceable, then this Agreement will be construed as if not containing the provision held to
be invalid, and the rights and obligations of the parties will be construed and enforced accordingly.

 

(b) Assignment
by Company. Nothing in this Agreement precludes the Company from consolidating or merging into or with, or transferring all or
substantially all of its assets to, another corporation or entity that assumes this Agreement and all obligations and undertakings hereunder.
Upon any consolidation, merger or transfer of assets and assumption, the term “Company” means any other corporation or entity,
as appropriate, and this Agreement will continue in full force and effect. This Agreement and all of Executive’s rights and obligations
hereunder are personal to Executive and may not be transferred or assigned by Executive at any time.

 

(c) Entire
Agreement. This Agreement (and any agreements referred to herein) and any agreements concerning equity compensation or other
benefits, embody the parties’ complete agreement with respect to the subject matter in this Agreement and supersede any prior written
or contemporaneous oral, understandings or agreements between the parties that may have related in any way to the subject matter in this
Agreement, including but not limited to any offer letter provided to or signed by Executive. This Agreement may be amended only in writing
executed by the Company and Executive.

 

    	 	-9-	 

     

    

 

(d) Governing
Law. Because it is mutually agreed that it is in the best interests of the Company and all of its employees that a uniform body
of law consistently interpreted be applied to the employment agreements to which the Company is a party, the laws of the State of California
will govern the interpretation and application of all of the provisions of this Agreement.

 

(e) Notice.
Any notice required or permitted under this Agreement must be in writing and will be deemed to have been given when delivered personally
or by overnight courier service or three days after being sent by mail, postage prepaid, at the address indicated below or to such changed
address as such person may subsequently give such notice of:

 

	 	 	 
	 	if
    to the Company:	Lygos
    Holdings, Inc.
	 	 	1249
                                            Eighth St.

    Berkeley,
    CA 94710

	 	 	 
	 	 	 
	 	 if
    to Executive:	Daniel
    O’Brien
	 	 	3-1287
    Verdier Ave Brentwood Bay, BC, 
	 	 	Canada, V8M 1H1

 

(f) Withholding.
All of Executive’s compensation under this Agreement will be subject to deduction and withholding authorized or required by applicable
law.

 

(g) Non-Waiver;
Construction; Counterparts. The failure in any one or more instances of a party to insist upon performance of any of the terms,
covenants or conditions of this Agreement, to exercise any right or privilege conferred in this Agreement, or the waiver by that party
of any breach of any of the terms, covenants or conditions of this Agreement, will not be construed as a subsequent waiver of any such
terms, covenants, conditions, rights or privileges, but the waiver will continue and remain in full force and effect as if no such forbearance
or waiver had occurred. No waiver is effective unless it is in writing and signed by an authorized representative of the waiving party.
This Agreement will be construed fairly as to both parties and not in favor of, or against, either party, regardless of which party prepared
the Agreement. This Agreement may be executed in multiple counterparts, each of which will be deemed to be an original, and all such
counterparts will constitute but one instrument.

 

(h) Successors
and Assigns. This Agreement is solely for the benefit of the parties and their respective successors, assigns, heirs and legatees.
Nothing in this Agreement will be construed to provide any right to any other entity or individual.

 

(i) Indemnification.
The Company agrees to indemnify the Executive to the fullest extent provided under the Company’s limited liability company agreement
and By-Laws, on the same terms and conditions as indemnification is generally provided to the Company’s officers and directors,
in the event that he was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding,
by reason of the fact that the Executive is or was a director, officer, employee or agent of the Company or any of its affiliates; provided,
however, that the Executive is not entitled to indemnification under this Section 9(i) relating to any claims, actions, suits
or proceedings arising from his breach of this Agreement.

 

    	 	-10-	 

     

    

 

10. Dispute
Resolution. Any dispute, controversy, or claim, whether contractual or non-contractual, including without limitation any federal
or state statutory claim, common law or tort claim, or claim for attorneys’ fees, between the parties arising directly or indirectly
out of or connected with this Agreement and/or the parties’ employment relationship, unless mutually settled by the parties hereto,
must be resolved by binding arbitration conducted pursuant to the rules of the American Arbitration Association (the “AAA”)
in effect at the time. The parties agree that before proceeding to arbitration, they will mediate their dispute(s) before a mutually
selected mediator. If the parties are unable to mutually select a mediator within thirty (30) days (or as otherwise agreed), then either
party may request the AAA’s assistance in appointing a mediator. Any arbitration will be conducted by an arbitrator mutually selected
by the parties. If the parties are unable to mutually select an arbitrator within thirty (30) days (or as otherwise agreed), then either
party may request the AAA’s assistance in selecting an arbitrator. All such disputes, controversies or claims will be conducted
by a single arbitrator, unless the parties mutually agree that the arbitration will be conducted by a panel of three arbitrators. The
arbitration shall be conducted pursuant to Employment Arbitration Rules of the AAA in effect at the time, or as otherwise agreed. The
arbitrator(s) may award any relief available in a court of competent jurisdiction. The resolution of the dispute by the arbitrator(s)
will be final, binding, nonappealable (except as provided by the Federal Arbitration Act) and fully enforceable by a court of competent
jurisdiction pursuant to the Federal Arbitration Act. The arbitration award will be in writing and will include a statement of the reasons
for the award. The arbitration will be held at the location that is mutually agreed to by the parties. The Company will initially pay
all AAA, mediation, and arbitrator’s fees and costs. The arbitrator(s) may award reasonable attorneys’ fees and/or costs
to the prevailing party. The Company and the Executive agree that each may bring claims against the other in an individual capacity only,
and not as a class representative or class member in any purported collective, class or representative proceeding. Further, unless both
the Company and the Executive agree otherwise, the Arbitrator may not consolidate more than one party’s claims into a single arbitration
proceeding and may not otherwise preside over any form of a collective, class or representative proceeding.

 

    	 	-11-	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first above written.

 

	 	FLEXIBLE
    SOLUTIONS INTERNATIONAL, INC.,
	 	 	 
	 	By:	/s/
    John Bientjes
	 	 	 
	 	Name:	John
    Bientjes
	 	 	 
	 	Title:
	Director,
    Audit Committee Chair and Compensation Committee Member
	 	 	 
	 	EXECUTIVE
	 	 	 
	 	/s/
    Daniel O’Brien
	 	 	 
	 	Name:
    	Daniel
    O’Brien

 

Attachment
A: Confidential Information and Invention Assignment Agreement

 

    	 	-12-	 

     

    

 

ATTACHMENT
A

 

CONFIDENTIAL
INFORMATION AND INVENTION ASSIGNMENT AGREEMENT

 

[See
Attached]

 

    	 	-13-	 

     

    

 

Flexible
Solutions International, inc.

 

CONFIDENTIAL
INFORMATION AND

INVENTION ASSIGNMENT AGREEMENT

 

Employee
Name: _Daniel B. O’Brien______

 

Effective
Date: _April 17, 2022_____

 

As
a condition of my becoming employed (or my employment being continued) by Flexible Solutions International, Inc., an Alberta corporation,
or any of its current or future subsidiaries, affiliates, successors or assigns (collectively, the “Company”), and
in consideration of my employment with the Company and my receipt of the compensation now and hereafter paid to me by the Company, the
receipt of Confidential Information (as defined below) while associated with the Company, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, I hereby agree to the following:

 

1.
Relationship. This Confidential Information and Invention Assignment Agreement (this “Agreement”) will
apply to my employment relationship with the Company. If that relationship ends and the Company, within one (1) year thereafter, either
reemploys me or engages me as a consultant, I agree that this Agreement will also apply to such later employment or consulting relationship,
unless the Company and I otherwise agree in writing. Any employment or consulting relationship between the parties hereto, whether commenced
prior to, upon or after the date of this Agreement, is referred to herein as the “Relationship.”

 

2.
Applicability to Past Activities. The Company and I acknowledge that I may have performed work, activities, services or
made efforts on behalf of or for the benefit of the Company, or related to the current or prospective business of the Company in anticipation
of my involvement with the Company, that would have been within the scope of my duties under this agreement if performed during the term
of this Agreement, for a period of time prior to the Effective Date of this Agreement (the “Prior Period”). Accordingly,
if and to the extent that, during the Prior Period: (i) I received access to any information from or on behalf of the Company that would
have been Confidential Information (as defined below) if I received access to such information during the term of this Agreement; or
(ii) I (a) conceived, created, authored, invented, developed or reduced to practice any item (including any intellectual property rights
with respect thereto) on behalf of or for the benefit of the Company, or related to the current or prospective business of the Company
in anticipation of my involvement with the Company, that would have been an Invention (as defined below) if conceived, created, authored,
invented, developed or reduced to practice during the term of this Agreement; or (b) incorporated into any such item any pre-existing
invention, improvement, development, concept, discovery or other proprietary information that would have been a Prior Invention (as defined
below) if incorporated into such item during the term of this Agreement; then any such information shall be deemed “Confidential
Information” hereunder and any such item shall be deemed an “Invention” or “Prior Invention” hereunder,
and this Agreement shall apply to such activities, information or item as if disclosed, conceived, created, authored, invented, developed
or reduced to practice during the term of this Agreement.

 

    	 	-14-	 

     

    

 

3.
Confidential Information.

 

(a)
Protection of Information. I understand that during the Relationship, the Company intends to provide me with certain information,
including Confidential Information (as defined below), without which I would not be able to perform my duties to the Company. At all
times during the term of the Relationship and thereafter, I shall hold in strictest confidence, and not use, except for the benefit of
the Company to the extent necessary to perform my obligations to the Company under the Relationship, and not disclose to any person,
firm, corporation or other entity, without written authorization from the Company in each instance, any Confidential Information that
I obtain, access or create during the term of the Relationship, whether or not during working hours, until such Confidential Information
becomes publicly and widely known and made generally available through no wrongful act of mine or of others who were under confidentiality
obligations as to the item or items involved. I shall not make copies of such Confidential Information except as authorized by the Company
or in the ordinary course of my obligations to the Company under the Relationship.

 

(b)
Confidential Information. I understand that “Confidential Information” means any and all information
and physical manifestations thereof not generally known or available outside the Company and information and physical manifestations
thereof entrusted to the Company in confidence by third parties, whether or not such information is patentable, copyrightable or otherwise
legally protectable. Confidential Information includes, without limitation: (i) Company Inventions (as defined below); and (ii) technical
data, trade secrets, know-how, research, product or service ideas or plans, software codes and designs, algorithms, developments, inventions,
patent applications, laboratory notebooks, processes, formulas, techniques, biological materials, mask works, engineering designs and
drawings, hardware configuration information, agreements with third parties, lists of, or information relating to, employees and consultants
of the Company (including, but not limited to, the names, contact information, jobs, compensation, and expertise of such employees and
consultants), lists of, or information relating to, suppliers and customers (including, but not limited to, customers of the Company
on whom I called or with whom I became acquainted during the Relationship), price lists, pricing methodologies, cost data, market share
data, marketing plans, licenses, contract information, business plans, financial forecasts, historical financial data, budgets or other
business information disclosed to me by the Company either directly or indirectly, whether in writing, electronically, orally, or by
observation.

 

(c)
Third Party Information. My agreements in this Section 3 are intended to be for the benefit of the Company and any third
party that has entrusted information or physical material to the Company in confidence. During the term of the Relationship and thereafter,
I will not improperly use or disclose to the Company any confidential, proprietary or secret information of my former employer(s) or
any other person, and I will not bring any such information onto the Company’s property or place of business.

 

(d)
Other Rights. This Agreement is intended to supplement, and not to supersede, any rights the Company may have in law or
equity with respect to the protection of trade secrets or confidential or proprietary information.

 

    	 	-15-	 

     

    

 

(e)
U.S. Defend Trade Secrets Act. Notwithstanding the foregoing, the U.S. Defend Trade Secrets Act of 2016 (“DTSA”)
provides that an individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure
of a trade secret that is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or
to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (iii) in a complaint or
other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, DTSA provides that an individual
who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney
of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the
trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.

 

4.
Ownership of Inventions.

 

(a)
Inventions Retained and Licensed. I have attached hereto, as Exhibit A, a complete list describing with particularity
all Inventions (as defined below) that, as of the Effective Date: (i) have been created by or on behalf of me, and/or (ii) are owned
exclusively by me or jointly by me with others or in which I have an interest, and that relate in any way to any of the Company’s
actual or proposed businesses, products, services, or research and development, and which are not assigned to the Company hereunder (collectively
“Prior Inventions”); or, if no such list is attached, I represent and warrant that there are no such Inventions at
the time of signing this Agreement, and to the extent such Inventions do exist and are not listed on Exhibit A, I hereby irrevocably
and forever waive any and all rights or claims of ownership to such Inventions. I understand that my listing of any Inventions on Exhibit
A does not constitute an acknowledgement by the Company of the existence or extent of such Inventions, nor of my ownership of such
Inventions. I further understand that I must receive the formal approval of the Company before commencing my Relationship with the Company.

 

(b)
Use or Incorporation of Inventions. If in the course of the Relationship, I use or incorporate into any of the Company’s
products, services, processes or machines any Invention not assigned to the Company pursuant to Section 4(d) of this Agreement in which
I have an interest, I will promptly so inform the Company in writing. Whether or not I give such notice, I hereby irrevocably grant to
the Company a nonexclusive, fully paid-up, royalty-free, assumable, perpetual, worldwide license, with right to transfer and to sublicense,
to practice and exploit such Invention and to make, have made, copy, modify, make derivative works of, use, sell, import, and otherwise
distribute such Invention under all applicable intellectual property laws without restriction of any kind.

 

(c)
Inventions. I understand that “Inventions” means discoveries, developments, concepts, designs, ideas,
know how, modifications, improvements, derivative works, inventions, trade secrets and/or original works of authorship, whether or not
patentable, copyrightable or otherwise legally protectable. I understand this includes, but is not limited to, any new product, machine,
article of manufacture, biological material, method, procedure, process, technique, use, equipment, device, apparatus, system, compound,
formulation, composition of matter, design or configuration of any kind, or any improvement thereon. I understand that “Company
Inventions” means any and all Inventions that I may solely or jointly author, discover, develop, conceive, or reduce to practice
during the period of the Relationship or otherwise in connection with the Relationship, except as otherwise provided in Section 4(g)
below.

 

    	 	-16-	 

     

    

 

(d)
Assignment of Company Inventions. I will promptly make full written disclosure to the Company, will hold in trust for the
sole right and benefit of the Company, and hereby assign to the Company, or its designee, all of my right, title and interest throughout
the world in and to any and all Company Inventions and all patent, copyright, trademark, trade secret and other intellectual property
rights and other proprietary rights therein. I hereby waive and irrevocably quitclaim to the Company or its designee any and all claims,
of any nature whatsoever, that I now have or may hereafter have for infringement of any and all Company Inventions. I further acknowledge
that all Company Inventions that are made by me (solely or jointly with others) within the scope of and during the period of the Relationship
are “works made for hire” (to the greatest extent permitted by applicable law) and are compensated by my salary. Any assignment
of Company Inventions includes all rights of attribution, paternity, integrity, modification, disclosure and withdrawal, and any other
rights throughout the world that may be known as or referred to as “moral rights,” “artist’s rights,” “droit
moral,” or the like (collectively, “Moral Rights”). To the extent that Moral Rights cannot be assigned under
applicable law, I hereby waive and agree not to enforce any and all Moral Rights, including, without limitation, any limitation on subsequent
modification, to the extent permitted under applicable law. If I have any rights to the Company Inventions, other than Moral Rights,
that cannot be assigned to the Company, I hereby unconditionally and irrevocably grant to the Company during the term of such rights,
an exclusive, irrevocable, perpetual, worldwide, fully paid and royalty-free license, with rights to sublicense through multiple levels
of sublicensees, to reproduce, distribute, display, perform, prepare derivative works of and otherwise modify, make, have made, sell,
offer to sell, import, practice methods, processes and procedures and otherwise use and exploit, such Company Inventions.

 

(e)
Maintenance of Records. I shall keep and maintain adequate and current written records of all Company Inventions made or
conceived by me (solely or jointly with others) during the term of the Relationship. The records may be in the form of notes, sketches,
drawings, flow charts, electronic data or recordings, laboratory notebooks, or any other format. The records will be available to and
remain the sole property of the Company at all times. I shall not remove such records from the Company’s place of business or systems
except as expressly permitted by Company policy which may, from time to time, be revised at the sole election of the Company for the
purpose of furthering the Company’s business. I shall deliver all such records (including any copies thereof) to the Company at
the time of termination of the Relationship as provided for in Section 5 and Section 6.

 

(f)
Intellectual Property Rights. I shall assist the Company, or its designee, at its expense, in every proper way in securing
the Company’s, or its designee’s, rights in the Company Inventions and any copyrights, patents, trademarks, mask work rights,
Moral Rights, or other intellectual property rights relating thereto in any and all countries, including the disclosure to the Company
or its designee of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths,
assignments, recordations, and all other instruments which the Company or its designee shall deem necessary in order to apply for, obtain,
maintain and transfer such rights, or if not transferable, waive and shall never assert such rights, and in order to assign and convey
to the Company or its designee, and any successors, assigns and nominees the sole and exclusive right, title and interest in and to such
Company Inventions, and any copyrights, patents, mask work rights or other intellectual property rights relating thereto. My obligation
to execute or cause to be executed, when it is in my power to do so, any such instrument or papers shall continue during and at all times
after the end of the Relationship and until the expiration of the last such intellectual property right to expire in any country of the
world. I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney-in-fact,
to act for and in my behalf and stead to execute and file any such instruments and papers and to do all other lawfully permitted acts
to further the application for, prosecution, issuance, maintenance or transfer of letters patent, copyright, mask work and other registrations
related to such Company Inventions. This power of attorney is coupled with an interest and shall not be affected by my subsequent incapacity.

 

    	 	-17-	 

     

    

 

(g)
Exception to Assignments. Subject to the requirements of applicable state law, if any, I understand that the Company Inventions
will not include, and the provisions of this Agreement requiring assignment of inventions to the Company do not apply to, any invention
which qualifies fully for exclusion under the provisions of applicable state law, if any, attached hereto as Exhibit B. In order
to assist in the determination of which inventions qualify for such exclusion, I will advise the Company promptly in writing, during
and for a period of twelve (12) months immediately following the termination of the Relationship, of all Inventions solely or jointly
conceived or developed or reduced to practice by me during the period of the Relationship.

 

5.
Company Property; Returning Company Documents. I acknowledge that I have no expectation of privacy with respect to the
Company’s telecommunications, networking or information processing systems (including, without limitation, files, e-mail messages,
and voice messages) and that my activity and any files or messages on or using any of those systems may be monitored or reviewed at any
time without notice. I further acknowledge that any property situated on the Company’s premises or systems and owned by the Company,
including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time
with or without notice. At the time of termination of the Relationship, I will deliver to the Company (and will not keep in my possession,
recreate or deliver to anyone else) any and all devices, records, data, notes, reports, proposals, lists, correspondence, specifications,
drawings, blueprints, sketches, laboratory notebooks, materials, flow charts, equipment, other documents or property, or reproductions
of any of the aforementioned items developed by me pursuant to the Relationship or otherwise belonging to the Company, its successors
or assigns.

 

6.
Termination Certification. In the event of the termination of the Relationship, I shall sign and deliver the “Termination
Certification” attached hereto as Exhibit C; however, my failure to sign and deliver the Termination Certification shall
in no way diminish my continuing obligations under this Agreement.

 

7.
Notice to Third Parties. During the periods of time during which I am restricted in taking certain actions by the terms
of Section 8 of this Agreement (the “Restriction Period”), I shall inform any entity or person with whom I may seek
to enter into a business relationship (whether as an owner, employee, independent contractor or otherwise) of my contractual obligations
under this Agreement. I acknowledge that the Company may, with or without prior notice to me and whether during or after the term of
the Relationship, notify third parties of my agreements and obligations under this Agreement. Upon written request by the Company, I
will respond to the Company in writing regarding the status of my employment or proposed employment with any party during the Restriction
Period.

 

    	 	-18-	 

     

    

 

8.
Solicitation of Employees, Consultants and Other Parties. As described above, I acknowledge that the Company’s Confidential
Information includes information relating to the Company’s employees, consultants, customers and others, and I will not use or
disclose such Confidential Information except as authorized by the Company in advance in writing. I further agree as follows:

 

(a)
Employees, Consultants. During the term of the Relationship, and for a period of twelve (12) months immediately following
the termination of the Relationship for any reason, whether with or without cause, I shall not, directly or indirectly, solicit any of
the Company’s employees or consultants to terminate their relationship with the Company, or attempt to solicit employees or consultants
of the Company, either for myself or for any other person or entity.

 

(b)
Other Parties. During the term of the Relationship, I will not influence any of the Company’s clients, licensors,
licensees or customers from purchasing Company products or services or solicit or influence or attempt to influence any client, licensor,
licensee, customer or other person either directly or indirectly, to direct any purchase of products and/or services to any person, firm,
corporation, institution or other entity in competition with the business of the Company.

 

9.
At-Will Relationship. I understand and acknowledge that, except as may be otherwise explicitly provided in a separate written
agreement between the Company and me, my Relationship with the Company is and shall continue to be at-will, as defined under applicable
law, meaning that either I or the Company may terminate the Relationship at any time for any reason or no reason, without further obligation
or liability, other than those provisions of this Agreement that explicitly continue in effect after the termination of the Relationship.

 

10.
Representations and Covenants.

 

(a)
Facilitation of Agreement. I shall execute promptly, both during and after the end of the Relationship, any proper oath,
and to verify any proper document, required to carry out the terms of this Agreement, upon the Company’s written request to do
so.

 

(b)
No Conflicts. I represent and warrant that my performance of all the terms of this Agreement does not and will not breach
any agreement I have entered into, or will enter into, with any third party, including without limitation any agreement to keep in confidence
proprietary information or materials acquired by me in confidence or in trust prior to or during the Relationship. I will not disclose
to the Company or use any inventions, confidential or non-public proprietary information or material belonging to any previous client,
employer or any other party. I will not induce the Company to use any inventions, confidential or non-public proprietary information,
or material belonging to any previous client, employer or any other party. I represent and warrant that I have listed on Exhibit A
all agreements (e.g., non-competition agreements, non-solicitation of customers agreements, non-solicitation of employees agreements,
confidentiality agreements, inventions agreements, etc.), if any, with a current or former client, employer, or any other person or entity,
that may restrict my ability to accept employment with the Company or my ability to recruit or engage customers or service providers
on behalf of the Company, or otherwise relate to or restrict my ability to perform my duties for the Company or any obligation I may
have to the Company. I shall not enter into any written or oral agreement that conflicts with the provisions of this Agreement.

 

    	 	-19-	 

     

    

 

(c)
Voluntary Execution. I certify and acknowledge that I have carefully read all of the provisions of this Agreement, that
I understand and have voluntarily accepted such provisions, and that I will fully and faithfully comply with such provisions.

 

11.
Electronic Delivery. Nothing herein is intended
to imply a right to participate in any of the Company’s equity incentive plans, however, if I do participate in such plan(s),
the Company may, in its sole discretion, decide to deliver any documents related to my participation in the Company’s equity
incentive plan(s) by electronic means or to request my consent to participate in such plan(s) by electronic means. I hereby consent to
receive such documents by electronic delivery and agree, if applicable, to participate in such plan(s) through an on-line
or electronic system established and maintained by the Company or a third party designated by the Company.

 

12.
Miscellaneous.

 

(a)
Governing Law. The validity, interpretation, construction and performance of this Agreement, and all acts and transactions
pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with
the laws of the State of Delaware, without giving effect to principles of conflicts of law.

 

(b)
Entire Agreement. This Agreement sets forth the entire agreement and understanding between the Company and me relating
to its subject matter and merges all prior discussions between us. No amendment to this Agreement will be effective unless in writing
signed by both parties to this Agreement. The Company shall not be deemed hereby to have waived any rights or remedies it may have in
law or equity, nor to have given any authorizations or waived any of its rights under this Agreement, unless, and only to the extent,
it does so by a specific writing signed by a duly authorized officer of the Company, it being understood that, even if I am an officer
of the Company, I will not have authority to give any such authorizations or waivers for the Company under this Agreement without specific
approval by the Board of Directors. Any subsequent change or changes in my duties, obligations, rights or compensation will not affect
the validity or scope of this Agreement.

 

(c)
Successors and Assigns. This Agreement will be binding upon my heirs, executors, administrators and other legal representatives,
and my successors and assigns, and will be for the benefit of the Company, its successors, and its assigns.

 

    	 	-20-	 

     

    

 

(d)
Notices. Any notice, demand or request required or permitted to be given under this Agreement shall be in writing and shall
be deemed sufficient when delivered personally or by overnight courier or sent by email, or 48 hours after being deposited in the U.S.
mail as certified or registered mail with postage prepaid, addressed to the party to be notified at such party’s address as set
forth on the signature page, as subsequently modified by written notice, or if no address is specified on the signature page, at the
most recent address set forth in the Company’s books and records.

 

(e)
Severability. If one or more of the provisions in this Agreement are deemed void or unenforceable to any extent in any
context, such provisions shall nevertheless be enforced to the fullest extent allowed by law in that and other contexts, and the validity
and force of the remainder of this Agreement shall not be affected. The Company and I have attempted to limit my right to use, maintain
and disclose the Company’s Confidential Information, and to limit my right to solicit employees and customers only to the extent
necessary to protect the Company from unfair competition. Should a court of competent jurisdiction determine that the scope of the covenants
contained in Section 8 exceeds the maximum restrictiveness such court deems reasonable and enforceable, the parties intend that the court
should reform, modify and enforce the provision to such narrower scope as it determines to be reasonable and enforceable under the circumstances
existing at that time.

 

(f)
Remedies. I acknowledge that violation of this Agreement by me may cause the Company irreparable harm, and therefore I
agree that the Company will be entitled to seek extraordinary relief in court, including, but not limited to, temporary restraining orders,
preliminary injunctions and permanent injunctions without the necessity of posting a bond or other security (or, where such a bond or
security is required, that a $1,000 bond will be adequate), in addition to and without prejudice to any other rights or remedies that
the Company may have for a breach of this Agreement.

 

(g)
Advice of Counsel. I acknowledge THAT, IN EXECUTING THIS AGREEMENT, I
Have HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND I Have read
and understood ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON
OF THE DRAFTING OR PREPARATION HEREOF.

 

(h)
Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered
shall be deemed an original, and all of which together shall constitute one and the same agreement. Execution of a facsimile or scanned
copy will have the same force and effect as execution of an original, and a facsimile or scanned signature will be deemed an original
and valid signature.

 

[Signature
Page Follows]

 

    	 	-21-	 

     

    

 

The
parties have executed this Confidential Information and Invention Assignment Agreement on the respective dates set forth below, to be
effective as of the Effective Date first above written.

 

	 	the
    company:
	 	 
	 	FLEXIBLE
    SOLUTIONS INTERNATIONAL, inc.
	 	 	 
	 	By:	/s/
    John Bientjes
	 	 	(Signature)
	 	 	 
	 	Name:	John
Bientjes
	 	Title:
    	Director,
    Audit Committee Chair and Compensation Committee Member
	 	 	 
	 	Address:
	 	 
	 	46081
    Greenwood Dr.
	 	Chilliwack,
    BC
	 	Canada
    V2R 4C9
	 	 	 
	 	Date:
    	April
    17, 2022
	 	 	 
	 	Employee:
	 	 	 
	 	Daniel B. O’Brien
	 	(Print Name)
	 	 	 
	 	/s/
    Daniel B. O’Brien 
	 	(Signature)
	 	 	 
	 	Address:
	 	 
	 	3-1287
    Verdier Ave
	 	Brentwood
    Bay, BC,
	 	Canada,
    V8M 1H1
	 	 	 
	 	Email:
    	dan@flexiblesolutions.com
	 	 	 
	 	Date:
    	April
    17, 2022

 

CONFIDENTIAL
INFORMATION AND INVENTION

ASSIGNMENT
AGREEMENT OF FLEXIBLE SOLUTIONS INTERNATIONAL, INC.

 

    	 

     

    

 

EXHIBIT
A

 

LIST
OF PRIOR INVENTIONS

AND ORIGINAL WORKS OF AUTHORSHIP

EXCLUDED UNDER SECTION 4(a) AND CONFLICTING AGREEMENTS DISCLOSED UNDER SECTION 10(b)

 

The
following is a list of (i) all Inventions that, as of the Effective Date: (A) have been created by me or on my behalf, and/or (B) are
owned exclusively by me or jointly by me with others or in which I have an interest, and that relate in any way to any of the Company’s
actual or proposed businesses, products, services, or research and development, and which are not assigned to the Company hereunder and
(ii) all agreements, if any, with a current or former client, employer, or any other person or entity, that may restrict my ability to
accept employment with the Company or my ability to recruit or engage customers or service providers on behalf of the Company, or otherwise
relate to or restrict my ability to perform my duties for the Company or any obligation I may have to the Company:

 

	Title
	 	Date
	 	Identifying
    Number

    or Brief Description
	 	 	 	 	 

 

Except
as indicated above on this Exhibit, I have no inventions, improvements or original works to disclose pursuant to Section 4(a) of this
Agreement and no agreements to disclose pursuant to Section 10(b) of this Agreement.

 

___
Additional sheets attached

 

Signature
of Employee: ______________________________

 

Print
Name of Employee: _____________________________

 

Date:
___________________________________________

 

    	 

     

    

 

EXHIBIT
B

 

Not
applicable.

 

    	 

     

    

 

EXHIBIT
C

 

TERMINATION
CERTIFICATION

 

This
is to certify that I do not have in my possession, nor have I failed to return, any devices, records, data, notes, reports, proposals,
lists, correspondence, specifications, drawings, blueprints, sketches, laboratory notebooks, flow charts, materials, equipment, other
documents or property, or copies or reproductions of any aforementioned items belonging to Flexible Solutions International, Inc., an
Alberta corporation, its subsidiaries, affiliates, successors or assigns (collectively, the “Company”).

 

I
further certify that I have complied with all the terms of the Company’s Confidential Information and Invention Assignment Agreement
(the “Confidentiality Agreement”) signed by me, including the reporting of any Inventions (as defined therein), conceived
or made by me (solely or jointly with others) covered by the Confidentiality Agreement, and I acknowledge my continuing obligations under
the Confidentiality Agreement.

 

I
further agree that, in compliance with the Confidentiality Agreement, I will preserve as confidential all trade secrets, confidential
knowledge, data or other proprietary information relating to products, processes, know-how, designs, formulas, developmental or experimental
work, computer programs, data bases, other original works of authorship, customer lists, business plans, financial information or other
subject matter pertaining to any business of the Company or any of its employees, clients, consultants or licensees.

 

I
further agree that for twelve (12) months immediately following the termination of my Relationship with the Company, I shall not either
directly or indirectly solicit any of the Company’s employees or consultants to terminate their relationship with the Company,
or attempt to solicit employees or consultants of the Company, either for myself or for any other person or entity.

 

Further,
I agree that I shall not use any Confidential Information of the Company to influence any of the Company’s clients or customers
from purchasing Company products or services or to solicit or influence or attempt to influence any client, customer or other person
either directly or indirectly, to direct any purchase of products and/or services to any person, firm, corporation, institution or other
entity in competition with the business of the Company.

 

	Date:	 	 	Employee:
	 	 	 	 
	 	 	 	 
	 	 	 	(Print
    Employee’s Name)
	 	 	 	 
	 	 	 	 
	 	 	 	*(Signature)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}]]